StockVS

Envista Holdings Corporation (NVST) 주식 분석

의료

Envista Holdings Corporation

$23.50

+$0.07 (+0.30%)

최종 업데이트: 2026년 5월 26일

가격 추이

최신 뉴스

제3자 소스에서 제공된 뉴스입니다. 투자 조언이 아닙니다.

분석

회사 개요

Envista Holdings Corporation is a prominent entity within the healthcare sector, specifically focusing on the development, manufacturing, and marketing of dental products across the United States, China, and international markets. The company operates through two primary business segments, namely Specialty Products & Technologies and Equipment & Consumables, serving a diverse range of dental professionals and consumers. Operating as a mid-to-large-cap public company, Envista holds a total market capitalization of $4.16B and employs approximately 12,000 individuals globally. Its trailing twelve-month revenue stands at $2.72B, which, combined with its substantial workforce and market capitalization, positions the firm as a significant player in the medical instruments and supplies industry. These financial metrics suggest that the company has established a robust operational footprint capable of generating substantial top-line growth while maintaining a significant presence in the global dental supply chain.

재무 건전성

The company reported a trailing twelve-month revenue of $2.72B, yet its net income for the same period was $47.00M, indicating a significant gap between revenue and profit that highlights a capital-intensive cost structure with relatively low profitability on a bottom-line basis. This disparity is further reflected in the EBITDA figure of $361.50M, which provides a clearer view of operational cash generation before the heavy impact of interest, taxes, depreciation, and amortization. The free cash flow generated amounts to $232.76M, demonstrating that the company retains sufficient liquidity to fund operations, invest in R&D, or manage debt obligations without needing to rely solely on external financing. Profitability analysis reveals a gross margin of 55.0%, an operating margin of 10.7%, and a profit margin of 1.7%, suggesting that while the core production and sales efficiency is high, significant operational expenses and tax burdens compress the final net income. In terms of solvency, Envista holds $1.21B in cash against total debt of $1.60B, resulting in a debt-to-equity ratio of 51.43%, which indicates a leveraged balance sheet where debt obligations exceed available cash reserves. Despite the leverage, the current ratio of 2.38 suggests a strong short-term liquidity position, as current assets are more than double the current liabilities, ensuring the ability to meet short-term obligations comfortably. Furthermore, the return on equity is calculated at 1.6% and the return on assets at 2.8%, metrics that reveal that the management team's effectiveness in generating returns on shareholder equity and total assets is currently modest relative to the company's asset base.

밸류에이션 평가

Valuation metrics present a complex picture where the trailing P/E ratio of 90.32 significantly diverges from the forward P/E of 16.22, implying that the market currently prices in a massive multiple of historical earnings but expects a substantial correction or re-rating of earnings in the future to bring the valuation in line with forward expectations. The price-to-book ratio stands at 1.33, indicating that the market values the company at a 33% premium over its net asset book value, which often occurs in sectors with intangible assets or strong brand equity despite current earnings pressures. Alternative valuation measures such as the price-to-sales ratio of 1.53 and an EV/EBITDA of 12.53 provide additional context, suggesting that the company trades at a premium relative to its sales but at a more reasonable multiple of its enterprise earnings power when compared to historical averages for the sector. The stock price has fluctuated within a 52-week range between a low of $14.22 and a high of $30.42, meaning the current trading price sits somewhere within this historical volatility band, reflecting recent market sentiment shifts. The beta value of 0.98 indicates that the stock's price volatility is nearly identical to the broader market, suggesting that Envista moves in tandem with general market trends rather than exhibiting extreme defensive or aggressive characteristics.

Growth & Income

Envista has demonstrated robust top-line expansion with revenue growth of 15.0% year-over-year, while earnings growth for the trailing twelve months reached an extraordinary 3146.1% year-over-year, indicating that earnings are growing at a rate vastly disproportionate to revenue, likely driven by a one-time event or a significant adjustment in the non-recurring income figures rather than sustainable operational scaling. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% payout ratio figure, which signifies a strategic decision to reinvest all available earnings directly into business growth, research, and development rather than returning capital to shareholders. This approach contrasts with mature companies that prioritize dividend income, focusing instead on capital allocation toward future revenue streams to sustain the high growth trajectory observed in recent periods. Overall, the growth and income profile of Envista is characterized by aggressive reinvestment and exceptional earnings volatility rather than consistent dividend income or stable revenue-driven profit growth.

동종업체 비교

Envista Holdings Corporation (NVST) 은(는) 의료 기기 및 용품 산업에서 운영됩니다. 시가총액 기준으로 가장 가까운 동종업체와의 비교는 다음과 같습니다:

기업명 티커 시가총액 PER
Envista Holdings Corporation NVST $3.81B 57.1
Intuitive Surgical, Inc. ISRG $154.64B 53.2
Becton, Dickinson and Company BDX $40.71B 25.8
Alcon Inc. ALC $33.02B 40.5

의료 기기 및 용품 산업 평균 PER은 208.0배입니다. Envista Holdings Corporation의 PER은 57.1입니다.

이 분석은 AI가 생성한 것으로 정보 제공 목적으로만 사용되며 투자 조언이 아닙니다. 데이터가 지연되거나 부정확할 수 있습니다. 투자 결정을 내리기 전에 항상 직접 조사하고 자격을 갖춘 재무 상담사와 상담하세요.

Envista Holdings Corporation 소개

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

회사 설명은 영어로 표시됩니다.

웹사이트 방문 →

주요 지표

시가총액
$3.81B
PER
57.15
52주 최고가
$30.42
52주 최저가
$17.03
평균 거래량
2.88M
베타
0.93

데이터는 yfinance를 통해 Yahoo Finance에서 제공됩니다. 매일 업데이트.

기업 정보

거래소
NYSE
국가
United States
직원 수
12,000